GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Galderma Group AG (CHIX:GALDz) » Definitions » ROE %

Galderma Group AG (CHIX:GALDZ) ROE % : 1.23% (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Galderma Group AG ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Galderma Group AG's annualized net income for the quarter that ended in Jun. 2024 was CHF84 Mil. Galderma Group AG's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was CHF6,821 Mil. Therefore, Galderma Group AG's annualized ROE % for the quarter that ended in Jun. 2024 was 1.23%.

The historical rank and industry rank for Galderma Group AG's ROE % or its related term are showing as below:

CHIX:GALDz' s ROE % Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.62
Current: 0.62

During the past 0 years, Galderma Group AG's highest ROE % was 0.62%. The lowest was 0.00%. And the median was 0.00%.

CHIX:GALDz's ROE % is ranked worse than
61.66% of 965 companies
in the Drug Manufacturers industry
Industry Median: 4.49 vs CHIX:GALDz: 0.62

Galderma Group AG ROE % Historical Data

The historical data trend for Galderma Group AG's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galderma Group AG ROE % Chart

Galderma Group AG Annual Data
Trend
ROE %

Galderma Group AG Semi-Annual Data
Jun23 Jun24
ROE % - 1.23

Competitive Comparison of Galderma Group AG's ROE %

For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galderma Group AG's ROE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's ROE % distribution charts can be found below:

* The bar in red indicates where Galderma Group AG's ROE % falls into.



Galderma Group AG ROE % Calculation

Galderma Group AG's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

Galderma Group AG's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Jun. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=84.018/( (0+6821.482)/ 1 )
=84.018/6821.482
=1.23 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Galderma Group AG  (CHIX:GALDz) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=84.018/6821.482
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(84.018 / 3961.322)*(3961.322 / 11243.11)*(11243.11 / 6821.482)
=Net Margin %*Asset Turnover*Equity Multiplier
=2.12 %*0.3523*1.6482
=ROA %*Equity Multiplier
=0.75 %*1.6482
=1.23 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=84.018/6821.482
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (84.018 / 137.646) * (137.646 / 564.882) * (564.882 / 3961.322) * (3961.322 / 11243.11) * (11243.11 / 6821.482)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.6104 * 0.2437 * 14.26 % * 0.3523 * 1.6482
=1.23 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Galderma Group AG ROE % Related Terms

Thank you for viewing the detailed overview of Galderma Group AG's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Galderma Group AG Business Description

Comparable Companies
Traded in Other Exchanges
Address
Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a standalone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 45% of net sales from the US and employs around 6,600 people.

Galderma Group AG Headlines

No Headlines